VBI Vaccines (VBIV) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free VBIV Stock Alerts $0.60 +0.01 (+1.70%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 18 at 2:30 AMVBI Vaccines Reports Full Year 2023 Financial Resultsbusinesswire.com - April 16 at 8:00 AMVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesbusinesswire.com - April 11 at 4:05 PMVBI Vaccines secures $2 million in direct offeringinvesting.com - April 11 at 3:23 PMVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesbusinesswire.com - April 9 at 2:45 PMVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastomabusinesswire.com - April 3 at 8:00 AMVBI Vaccines expands collaboration with Canadian governmentmsn.com - April 2 at 5:12 PMVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platformbusinesswire.com - April 2 at 8:00 AMVBI Vaccines Inc. (VBIV)finance.yahoo.com - March 31 at 8:25 AMBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:40 AMNorth Carolina biotech inks $30M deal to expand its global pipelinebizjournals.com - February 15 at 3:37 PMVBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciencesmsn.com - February 14 at 6:34 PMStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccinesfinance.yahoo.com - February 14 at 1:33 PMWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarketbenzinga.com - February 14 at 8:33 AMVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciencesfinance.yahoo.com - February 14 at 8:33 AMVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciencesbusinesswire.com - February 14 at 7:00 AMBrii Biosciences To Buy VBI's IP Rights In BRII-179markets.businessinsider.com - February 13 at 10:32 PMBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Suppliesprnewswire.com - February 13 at 7:04 PMVBI Vaccines Secures Forbearance Agreement Extensionsmsn.com - February 7 at 9:52 AMVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meetingfinance.yahoo.com - November 20 at 10:15 AMVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63Mmsn.com - November 14 at 6:09 PMVBI Vaccines Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:09 PMVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Programfinance.yahoo.com - October 26 at 8:41 AMThese Are the Side Effects You Can Expect From the New COVID Vaccine, According to Immunologistsyahoo.com - September 30 at 8:39 PMVBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concernmsn.com - September 27 at 3:58 PMVBI Vaccines To Advance Coronavirus Vaccine Programmarkets.businessinsider.com - September 27 at 3:58 PMVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concernfinance.yahoo.com - September 27 at 9:40 AMVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMfinance.yahoo.com - September 7 at 10:59 AMVBI Vaccines gains after Phase 2 data for Hep B candidatemsn.com - September 6 at 8:18 AMVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis Bfinance.yahoo.com - September 6 at 8:18 AMVBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M misses by $0.19Mseekingalpha.com - August 14 at 5:02 PMVBI Vaccines Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 14 at 5:02 PMVBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Sharesfinance.yahoo.com - July 24 at 10:08 AM7 Biotech Stocks to Sell in Julyfinance.yahoo.com - July 19 at 7:50 AMDurham biotech secures global rights to hepatitis B treatmentbizjournals.com - July 10 at 12:01 AMVBI Vaccines Stock Cut in Half after Announcing Public Offeringmsn.com - July 6 at 6:56 PMVBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offeringfinance.yahoo.com - July 6 at 1:56 PMWhy Is VBI Vaccines (VBIV) Stock Down 40% Today?investorplace.com - July 6 at 11:02 AMBrii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Curebenzinga.com - July 6 at 8:55 AMVBI Vaccines, Brii Biosciences Expand Hepatitis B Immunotherapy Pactmsn.com - July 6 at 8:55 AMVBI Vaccines down 3% after hours on public offeringseekingalpha.com - July 5 at 7:17 PMVBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus ...businesswire.com - July 5 at 7:17 PMVBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royaltiesfinance.yahoo.com - July 5 at 7:17 PMVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrantsfinance.yahoo.com - July 5 at 7:17 PMBrii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023finance.yahoo.com - June 25 at 8:31 AMVBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adultsfinance.yahoo.com - June 15 at 9:56 AMVBI Vaccines Announces Poster Presentation at EASL 2023finance.yahoo.com - June 7 at 8:49 AMVBI Vaccines Inc.'s (NASDAQ:VBIV) Intrinsic Value Is Potentially 30% Above Its Share Pricefinance.yahoo.com - June 4 at 2:23 PMInstrument Name Vbi Vaccines Inc CS Instrument Symbol (VBIV-Q)theglobeandmail.com - May 25 at 9:36 PMVBI Vaccines Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 15 at 10:33 AM Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. VBIV Media Mentions By Week VBIV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VBIV News Sentiment▼-0.470.41▲Average Medical News Sentiment VBIV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VBIV Articles This Week▼11▲VBIV Articles Average Week Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cocrystal Pharma News Today Kiora Pharmaceuticals News Today Edesa Biotech News Today NanoViricides News Today Orgenesis News Today Pieris Pharmaceuticals News Today Aytu BioPharma News Today Avalo Therapeutics News Today Imunon News Today Monopar Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VBIV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
